Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7
Benzinga Newsdesk 6 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.
Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.